Venlafaxina retard stadagen 225 mg capsulas duras de liberacion prolongada efg

Prospect: information for the user

Venlafaxine Retard Stadagen 75 mg hard capsules for prolonged releaseEFG

Venlafaxine Retard Stadagen 150 mg hard capsules for prolonged releaseEFG

Venlafaxine Retard Stadagen 225 mg hard capsules for prolonged releaseEFG

Read this prospect carefully before starting to take this medicine, as it contains important information for you.

• Keep this prospect, as you may need to read it again.
• If you have any doubts, consult your doctor or pharmacist.
• This medicine has been prescribed only for you, and you should not give it to other people even if they have the same symptoms as you, as it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospect. See section 4.

Prospect content

Venlafaxina Retard Stadagen is an antidepressant that belongs to a group of medications called serotonin and norepinephrine reuptake inhibitors (SNRIs). This group of medications is used to treat depression and other conditions such as anxiety disorders. The exact mechanism of how antidepressants work is not fully understood, but they may help increase levels of serotonin and norepinephrine in the brain.

Venlafaxina Retard Stadagen is a treatment for adults with depression. It is also a treatment for adults with the following anxiety disorders: generalized anxiety disorder, social anxiety disorder (fear or avoidance of social situations) and panic disorder (panic attacks). Treating depressive and anxiety disorders properly is important to help you feel better. If left untreated, your condition may not go away or may worsen and become harder to treat.

Do not take Venlafaxina Retard Stadagen

• If you are allergic to venlafaxine or any of the other ingredients of this medicine (listed in section 6).
• If you are also taking or have taken in the last 14 days, any medicine known as an irreversible monoamine oxidase inhibitor (IMAO), used to treat depression or Parkinson's disease. Taking an IMAO irreversible with venlafaxine may produce severe or potentially fatal side effects. Also, you should wait at least 7 days after stopping venlafaxine before taking any IMAO (see also the sections “Other medicines and Venlafaxina Retard Stadagen” and the information in that section on “Serotonin syndrome”).

Warnings and precautions

Consult your doctor or pharmacistbeforetaking venlafaxine if you:

• are taking other medicines that, taken with venlafaxine, may increase the risk of developing serotonin syndrome (see the section “Other medicines and Venlafaxina Retard Stadagen”)
• have eye problems, such as certain types of glaucoma (increased pressure in the eye).
• have a history of high blood pressure.
• have a history of heart problems.
• have been informed that your heart rhythm is altered.
• have a history of seizures (convulsions).
• have a history of low sodium levels in the blood (hyponatremia).
• have a history of bleeding disorders (tendency to develop ecchymoses or tendency to bleed easily) or if you are taking other medicines that may increase the risk of bleeding, e.g. warfarin (used to prevent blood clots) or if you are pregnant (see section “Pregnancy, breastfeeding and fertility”).
• have a history of, or if someone in your family has had, mania or bipolar disorder (feeling overexcited or euphoric).
• If you have a history of aggressive behavior.

Venlafaxina Retard Stadagen may cause a feeling of restlessness or difficulty sitting or staying still during the first weeks of treatment. You should consult your doctor if this happens.

Do not drink alcohol during treatment with venlafaxine, as it may cause extreme fatigue and unconsciousness. Taking it with certain medicines and/or alcohol may worsen the symptoms of depression and other conditions, such as anxiety disorders.

Suicidal thoughts and worsening of your depression or anxiety disorder

If you are depressed and/or have anxiety disorders, you may sometimes have thoughts of harming yourself or committing suicide. These thoughts may increase when you start taking antidepressants, as all these medicines take time to work, usually two weeks, although sometimes more. These thoughts may also occur when your dose is reduced or during the interruption of treatment with venlafaxina.

This is more likely to happen:

• if you have had previous thoughts of suicide or self-harm.
• if you are a young adult. Clinical trial information has shown an increased risk of suicidal behavior in young adults (less than 25 years old) with psychiatric disorders treated with antidepressants.

If you have thoughts of harming yourself or committing suicide at any time, contact your doctor or go to the hospital directly.

You may find it helpful to tell a close relative or friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You can also ask them to tell you if they think your depression or anxiety is getting worse, or if they are concerned about changes in your behavior.

Dry mouth

Dry mouth has been reported in 10% of patients treated with venlafaxine. This may increase the risk of tooth decay (caries). Therefore, you should take good care of your dental hygiene.

Diabetes

Your blood glucose levels may be affected by venlafaxine. Therefore, your doses of diabetes medicines may need to be adjusted.

Sexual problems

Some medicines in the group to which venlafaxine belongs (called SSRIs) may cause sexual symptoms (see section 4). In some cases, these symptoms persist after stopping treatment.

Children and adolescents

Venlafaxina should not be used normally in the treatment ofchildren and adolescents under 18 years. Also, you should know that in patients under 18 yearsthere is agreater risk of side effects such as suicidal thoughts,suicidal ideationand hostility (predominantly aggression, confrontational behavior and irritability) when taking this type of medicine. Despite this, your doctor may prescribe this medicine to patients under 18 years when they decide it is the best option for the patient. Ifyour doctorhas prescribed this medicine to a patient under 18 years and wants to discuss this decision,please returnto your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen in these patients under 18 years taking venlafaxina.

Also, the long-term safety in relation to growth, maturation and cognitive and behavioral development has not been demonstrated.

Other medicines and Venlafaxina Retard Stadagen

Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medicine.

Your doctor should decide if you can take venlafaxine with other medicines.

Do not start or stop taking any medicine, including those available over the counter, natural remedies and herbal remedies, without checking with your doctor or pharmacist.

• Inhibitors of monoamine oxidase used to treat depression or Parkinson's disease,should not be taken with venlafaxine. Tell your doctor if you have taken any of these medicines in the last 14 days. (IMAO: see section “What you need to know before starting to take Venlafaxina Retard Stadagen”)

• Serotonin syndrome:

A potentially fatal state, or reactions similar to Malignant Neuroleptic Syndrome (MNS) (see section “Possible side effects”) may occur with treatment with venlafaxine, particularly when taken with other medicines.

Examples of these medicines include:

• triptans (used for migraines)
• other medicines to treat depression, for example, SSRIs, SNRIs, tricyclic antidepressants or medicines containing lithium
• • medicines containing amphetamines (used to treat attention deficit hyperactivity disorder (ADHD), narcolepsy and obesity)
• medicines containing the antibiotic linezolid (used to treat infections)
• medicines containing moclobemide, an IMAO (used to treat depression)
• medicines containing sibutramine (used for weight loss)
• medicines containing opioids (e.g. buprenorphine, tramadol, fentanyl, tapentadol, pethidine, or pentazocine) used to treat severe pain
• medicines containing dextromethorphan (used to treat cough)
• medicines containing methadone (used to treat opioid addiction or to treat severe pain)
• medicines containing methylene blue (used to treat high levels of methaemoglobin in the blood)
• products containing St. John's Wort (also known as “Hypericum perforatum”, a natural remedy or herbal remedy used to treat mild depression)
• products containing tryptophan (used for problems such as sleep and depression).
• antipsychotics (used to treat a condition with symptoms such as hearing, seeing or feeling things that do not exist, false beliefs, unusual suspicion, unclear thinking and tendency to withdraw)

The signs and symptoms of serotonin syndrome may include a combination of the following: restlessness, hallucinations, loss of coordination, rapid heartbeat, increased body temperature, rapid changes in blood pressure, hyperactive reflexes, diarrhea, coma, nausea, vomiting.

In its most severe form, serotonin syndrome may resemble Malignant Neuroleptic Syndrome (MNS). The signs and symptoms of MNS may include a combination of fever, rapid heartbeat, sweating, severe muscle stiffness, confusion, increased muscle enzymes (determined by a blood test).

Inform your doctor immediately or go to the nearest hospital emergency department if you think you are experiencing serotonin syndrome.

Inform your doctor if you are taking medicines that may affect your heart rhythm.

Some examples of these medicines include:

• antiarrhythmics such as quinidine, amiodarone, sotalol or dofetilide (used to treat abnormal heart rhythm)
• antipsychotics such as thioridazine (see also “Serotonin syndrome” above)
• antibiotics such as erythromycin or moxifloxacin (used to treat bacterial infections)
• antihistamines (used to treat allergies)

The following medicines may also interact with venlafaxine and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medicines that contain:

• ketoconazole (an antifungal medicine)
• haloperidol or risperidone (to treat psychiatric conditions)
• metoprolol (a beta-blocker to treat high blood pressure and heart problems)

Taking Venlafaxina Retard Stadagen with food, drinks and alcohol

Venlafaxina should be taken with food (see section 3 “How to take Venlafaxina Retard Stadagen”).

Do not drink alcohol during treatment with venlafaxine. Taking it with alcohol may cause extreme fatigue and unconsciousness, and worsen the symptoms of depression and other conditions, such as anxiety disorders.

Pregnancy, breastfeeding and fertility

Pregnancy

If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine. You should only take venlafaxine after discussing the possible benefits and risks for the unborn baby with your doctor.

Make sure your midwife and/or doctor knows that you are taking venlafaxine. When taken during pregnancy, similar medicines (SSRIs) may increase the risk of a serious condition in the newborn, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and turn blue. These symptoms usually start within the first 24 hours after the baby's birth. If this happens to your baby, contact your midwife and/or doctor immediately.

If you take venlafaxine in the final stages of pregnancy, there may be a greater risk of heavy vaginal bleeding shortly after delivery, especially if you have a history of bleeding disorders. Your doctor or midwife should know that you are taking venlafaxine so they can advise you.

If you are taking this medicine during pregnancy, other symptoms your baby may have when born are feeding problems and breathing difficulties. If your baby has these symptoms when born and you are concerned, contact your doctor and/or midwife who can advise you.

Breastfeeding

Venlafaxine passes into breast milk. There is a risk of an effect on the baby. Therefore, you should discuss the case with your doctor and they will decide if you should stop breastfeeding or stop taking this medicine.

Driving and using machines

Do not drive or operate tools or machines until you know how this medicine affects you

Venlafaxina Retard Stadagen 150 mg contains sodium and the colourants yellow iron oxide (E 172) and red iron oxide (E 172)

Venlafaxina Retard Stadagen 225 mg contains the colourant carmoisine (E 122)

Carmoisine (E 122) may cause allergic reactions.

.

Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.consulte de nuevo a su médico o farmacéutico.

Dosage

Depression

The recommended initial dose is 75 mg per day. Your doctor may gradually increase the dose and if necessary, even more up to a maximum of 375 mg per day.

Panic Disorder

Your doctor will start with a lower dose (37.5 mg) and then gradually increase the dose. The maximum dose is 225 mg/day.

Generalized Anxiety Disorder or Social Anxiety Disorder

The recommended initial dose is 75 mg per day. The maximum dose is 225 mg/day.

Liver or kidney problems

Speak with your doctor as your dose of this medication may need to be different.

Administration Form

Take venlafaxine approximately at the same time every day, either in the morning or at night.

The capsules must be swallowed whole with liquids and should not be opened, crushed, chewed, or dissolved.

Venlafaxine should be taken with food.

Do not stop taking this medication without consulting your doctor (see section “If you stop treatment with Venlafaxina Retard Stadagen”).

If you take more Venlafaxina Retard Stadagen than you should

Contact your doctor or pharmacist immediately if you take more medication than prescribed by your doctor. You can also contact the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount taken.

Overdose can be life-threatening, especially with the simultaneous use of certain medications and/or alcohol (see “Taking Venlafaxina Retard Stadagen with other medications”).

The symptoms of a possible overdose may include palpitations, changes in alertness (ranging from drowsiness to coma), blurred vision, seizures or attacks, and vomiting.

If you forgot to take Venlafaxina Retard Stadagen

If you have not taken a dose, take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and take only one dose as usual. Do not take a double dose to compensate for the missed doses. Do not take more than the daily dose of venlafaxine prescribed in a day.

If you stop treatment with Venlafaxina Retard Stadagen

Do not stop taking your treatment or reduce the dose without consulting your doctor, even if you feel better. If your doctor thinks you no longer need venlafaxine, they may ask you to gradually reduce the dose before stopping treatment completely.

It is known that adverse effects occur when people stop using this medication, especially when it is stopped suddenly or if the dose is reduced very quickly. Some patients may experience symptoms such as suicidal thoughts, aggression, fatigue, dizziness, instability, headaches, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, agitation, confusion, tinnitus, numbness or, in rare cases, electric shock sensations, weakness, sweating, seizures, or symptoms similar to the flu, vision problems, and increased blood pressure (which can cause headaches, dizziness, tinnitus, sweating, etc.).

Your doctor will advise you on how to gradually stop treatment with venlafaxine. This may take several weeks or months. In some patients, the interruption may need to be very gradual over months or more. If you experience any of these or other symptoms that bother you, consult your doctor for advice.

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

Like all medications, this medication may cause side effects, although not everyone will experience them.

Severe side effects

If any of the following side effects occur, do not take more venlafaxine.Inform your doctor immediately, or go to the nearest hospital emergency room:

Uncommon (may affect up to 1 in 100 people)

• swelling of the face, mouth, tongue, throat, hands, or feet, and/or itchy, swollen, and blistered skin, difficulty swallowing or breathing.

Rare (may affect up to 1 in 1,000 people)

• chest tightness, wheezing, difficulty swallowing or breathing.
• severe skin rash, itching, or urticaria (raised, red, or pale areas of skin that often itch).
• signs and symptoms of serotonin syndrome, which may include agitation, hallucinations, loss of coordination, rapid heartbeat, increased body temperature, rapid changes in blood pressure, hyperactive reflexes, diarrhea, coma, nausea, vomiting.

In its most severe form, serotonin syndrome may resemble Malignant Neuroleptic Syndrome (MNS). The signs and symptoms of MNS may include a combination of fever, rapid heartbeat, sweating, severe muscle rigidity, confusion, increased muscle enzymes (determined by blood tests).

• signs of infection, such as fever, chills, shivering, headache, sweating, or symptoms similar to the flu. This may be due to a blood disorder that may increase the risk of infection.
• severe rash, which may lead to the formation of severe blisters and skin peeling.
• unexplained muscle pain, discomfort, or weakness. This may be a sign of rhabdomyolysis.

Unknown frequency (cannot be estimated from available data)

• signs and symptoms of a condition called "stress cardiomyopathy," which may include chest pain, difficulty breathing, dizziness, fainting, irregular heartbeat.

Other side effects that you should inform your doctor are (the frequency of these side effects are included in the list below "Other side effects that may occur"):

• cough, wheezing, and difficulty breathing that may be accompanied by a fever.
• black, tarry stools or blood in stools.
• itching, yellow eyes or skin, dark urine, which are symptoms of liver inflammation (hepatitis).
• heart problems, such as rapid or irregular heartbeat, increased blood pressure.
• eye problems, such as blurred vision, dilated pupils.
• nerve problems, such as dizziness, numbness, movement disorders (muscle spasms and rigidity), seizures, or convulsions.
• psychiatric problems, such as hyperactivity (unusual feeling of overexcitement).
• withdrawal effects (see section "How to take Venlafaxine Retard STADAGEN, if you interrupt treatment with Venlafaxine Retard STADAGEN").
• prolonged bleeding, if you cut or injure yourself, it may take a little longer than usual for the bleeding to stop.

Other side effects that may occur

Very common (may affect more than 1 in 10 people)

• dizziness, headache, somnolence
• insomnia
• nausea, dry mouth, constipation
• excessive sweating (including night sweats)

Common (may affect up to 1 in 10 people)

• decreased appetite
• confusion, feeling strange, lack of orgasm, decreased libido, agitation, nervousness, abnormal dreams
• tremor; a feeling of restlessness or inability to sit or stay still, numbness, altered taste perception, increased muscle tone
• visual disturbances, including blurred vision, dilated pupils, inability of the eye to automatically focus on distant objects
• ringing in the ears (tinnitus)
• rapid heartbeat, palpitations
• increased blood pressure, hot flashes
• difficulty breathing, yawning
• vomiting, diarrhea
• mild skin rash, itching
• increased urination, inability to urinate, difficulty urinating
• irregular menstrual periods, such as increased bleeding or irregular bleeding, abnormal ejaculation/orgasm (men), erectile dysfunction (impotence)
• weakness (asthenia), fatigue, chills
• weight gain or loss
• increased cholesterol

Uncommon (may affect up to 1 in 100 people)

• hyperactivity, rapid thoughts, and decreased need for sleep (mania)
• hallucinations, feeling disconnected from reality, abnormal orgasm, lack of feelings or emotions, feeling overexcited, grinding of teeth
• syncope, involuntary muscle movements, alteration of coordination and balance
• feeling dizzy (especially when standing up too quickly), decreased blood pressure
• vomiting blood, black, tarry stools, or blood in stools, which may be a sign of internal bleeding
• sensitivity to sunlight, petechiae, abnormal hair loss
• inability to control urination
• rigidity, spasms, and involuntary muscle movements
• slight changes in liver enzyme levels

Rare (may affect up to 1 in 1,000 people)

• seizures or convulsions
• cough, wheezing, and shortness of breath that may be accompanied by a fever
• disorientation and confusion, often accompanied by hallucinations (delirium)
• excessive water intake (known as SIADH)
• decreased sodium levels in the blood
• severe eye pain and reduced or blurred vision
• abnormal heartbeat, rapid or irregular, which may lead to fainting
• severe abdominal or back pain (which may indicate a serious problem in the intestine, liver, or pancreas)
• itching, yellow eyes or skin, dark urine, symptoms similar to the flu, which are symptoms of liver inflammation (hepatitis).

Very rare (may affect up to 1 in 10,000 people)

• prolonged bleeding, which may be a sign of a reduced number of platelets in the blood, leading to an increased risk of bruising or bleeding
• abnormal milk production
• unexpected bleeding, such as bleeding gums, blood in urine or vomit, or the sudden appearance of petechiae or bleeding from blood vessels (broken veins).

Unknown frequency (cannot be estimated from available data)

• suicidal thoughts and behavior, cases of suicidal thoughts and behavior have been reported during treatment with venlafaxine or shortly after stopping treatment (see section 2 "What you need to know before starting to take Venlafaxine Retard Stadagen").
• aggression
• dizziness
• excessive vaginal bleeding after childbirth (postpartum hemorrhage), see "Pregnancy, breastfeeding, and fertility" in section 2 for more information.

Blood tests

Venlafaxine may sometimes cause unwanted effects that you may not be aware of, such as increased blood pressure or abnormal heartbeat; slight changes in liver enzyme levels, sodium, or cholesterol. Less frequently, venlafaxine may reduce the function of platelets in the blood, leading to an increased risk of bruising or bleeding. Therefore, your doctor may wish to perform occasional blood tests, particularly if you have been taking venlafaxine for a long time.

Reporting side effects

Ifyou experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.

Keep this medication out of the sight and reach of children.

Do not usethis medication after the expiration date that appears on the blister pack and on the packaging, after CAD. The expiration date is the last day of the month indicated.

This medication does not require special storage conditions.

Do not use this medication if the capsules appear significantly discolored or show other signs of significant deterioration.

Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.

Composition of Venlafaxine Retard Stadagen

The active ingredient is venlafaxine.

Venlafaxine Retard Stadagen 75 mg hard capsules with prolonged releaseEFG:

Each capsule contains 84.9 mg of venlafaxine hydrochloride equivalent to 75 mg of venlafaxine.

The other components are:

Core: microcrystalline cellulose (E460), povidone, talc (E553b), anhydrous colloidal silica (E551), magnesium stearate (E572).

Capsule coating: ethylcellulose, copovidone.

Capsule cap:black iron oxide (E172), red iron oxide (E172), titanium dioxide(E171), gelatin.

Capsule body:black iron oxide (E172), red iron oxide (E172),dióxido de titanio(E171), gelatina, red ink (composition: shellac, propylene glycol, strong ammonia solution and red iron oxide (E172)).

Venlafaxine Retard Stadagen 150 mg hard capsules with prolonged releaseEFG:

Each capsule contains 169.8 mg of venlafaxine hydrochloride equivalent to 150 mg ofvenlafaxine.

The other components are:

Core: microcrystalline cellulose (E460), povidone, talc (E553b), anhydrous colloidal silica (E551), magnesium stearate (E572).

Capsule coating: ethylcellulose, copovidone.

Capsule cap: brilliant blue FCF (E133), allura red AC (E129), yellow orange S (E110), titanium dioxide (E171), gelatina

Capsule body: brilliant blue FCF (E133), allura red AC (E129), yellow orange S (E110), titanium dioxide (E171), gelatina, white ink (composition: shellac, propylene glycol, sodium hydroxide, povidone, titanium dioxide (E171)).

Venlafaxine Retard Stadagen 225 mg hard capsules with prolonged releaseEFG:

Each capsule contains 254.7 mg of venlafaxine hydrochloride equivalent to 225 mg of venlafaxine.

The other components are:

Core: microcrystalline cellulose (E460), povidone, talc (E553b), anhydrous colloidal silica (E551), magnesium stearate (E572)

Capsule coating: ethylcellulose, copovidone

Capsule cap: carmoisine (E122), titanium dioxide (E171), gelatina

Capsule body: carmoisine (E122), titanium dioxide (E171), gelatina, blue ink (composition: shellac, propylene glycol, strong ammonia solution and cochineal extract (E132)).

Appearance of the product and contents of the package

Venlafaxine Retard Stadagen 75 mgare hard gelatin capsules, size “1”, orange opaque/orange opaque, with thick and thin circular bands of red on the body and cap. The capsule contains 6 mini tablets coated with a film, white to off-white, round and biconvex, 12.5 mg each.

It is available in packages of 7, 10, 14, 20, 28, 30, 50, 56, 98, 100, 105 and 120 capsules packaged in blisters (PVC/Aclar-Aluminum or Aluminum-PVC/PVdC white opaque). Only some package sizes may be marketed.

Venlafaxine Retard Stadagen 150 mgare hard gelatin capsules, size “0”, dark orange/dark orange opaque, with thick and thin circular bands of white on the body and cap. The capsule contains 12 mini tablets coated with a film, white to off-white, round and biconvex, 12.5 mg each.

It is available in packages of 10, 14, 20, 28, 30, 50, 56, 98, 100, 105 and 120 capsules packaged in blisters (PVC/Aclar-Aluminum or Aluminum-PVC/PVdC white opaque). Only some package sizes may be marketed.

Venlafaxine Retard Stadagen 225 mgare hard gelatin capsules, size “00”, pink opaque/pink opaque, with thick and thin circular bands of blue on the body and cap. The capsule contains 18 mini tablets coated with a film, white to off-white, round and biconvex, 12.5 mg each.

It is available in packages of 10, 14, 20, 28, 30, 50 and 100 capsules packaged in blisters

(Aluminum-OPA/aluminum/PVC or Aluminum-PVC/Aclar white opaque or Aluminum-PVC/PVdC white opaque).Only some package sizes may be marketed.

Marketing authorization holder and responsible manufacturer:

Marketing authorization holder

STADA Laboratorios, S.L.

Frederic Mompou, 5

08960 Sant Just Desvern (Barcelona)

Spain

[email protected]

Responsible manufacturer

STADA Arzneimittel AG

Stadastrasse 2 – 18

61118 Bad Vilbel

Germany

or

Clonmel Healthcare Ltd.

Waterford Road

Clonmel, Co.Tipperary

Ireland

or

Sanico N.V

Veedijk 59,

B-2300 , Turnhout,

Belgium

This medicinal product is authorized in the member states of the European Economic Area with the following names:

Germany:Venlafaxin AL 37.5 mg Hartkapsel, retardiert

Venlafaxin AL 75 mg Hartkapsel, retardiert

Venlafaxin AL 150 mg Hartkapsel, retardiert

Venlafaxin AL 225 mg Hartkapsel, retardiert

Belgium:Venlafaxine EG 37.5 mg harde capsules met verlengde afgifte

Venlafaxine EG 75 mg harde capsules met verlengde afgifte

Venlafaxine EG 150 mg harde capsules met verlengde afgifte

Denmark:Efastad, hårde depotkapsler

Spain:Venlafaxina Retard Stadagen 75 mg hard capsules with prolonged release EFG

Venlafaxina Retard Stadagen 150 mg hard capsules with prolonged release EFG

Venlafaxina Retard Stadagen 225 mg hard capsules with prolonged release EFG

France:VENLAFAXINE EG LABO LP 37.5 mg, gélule à libération prolongée

VENLAFAXINE EG LABO LP 75 mg, gélule à libération prolongée

Ireland:Venex XL 37. 5 mg prolonged release capsules, hard

Venex XL 75 mg prolonged release capsules, hard

Venex XL 150 mg prolonged release capsules, hard

Luxembourg:Venlafaxine EG 37.5 mg gélules à libération prolongée

Venlafaxine EG 75 mg ggélules à libération prolongée

Venlafaxine EG 150 mg gélules à libération prolongée

Malta:Venex XL 37.5 mg Prolonged-release Capsules, hard

Venex XL 75 mg Prolonged-release Capsules, hard

Venex XL 150 mg Prolonged-release Capsules, hard

Portugal:Venlafaxina Ciclum 37.5 mg Cápsula de libertação prolongada

Venlafaxina Ciclum 75 mg Cápsula de libertação prolongada

Venlafaxina Ciclum 150 mg Cápsula de libertação prolongada

Venlafaxina Ciclum 225 mg Cápsula de libertação prolongada

Sweden:Efastad 75 mg depotkapslar, hårda

Efastad 150 mg depotkapslar, hårda

Last review date of this leaflet:March 2024

Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/